Shanghai Allink Biotherapeutics Co., Ltd.established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.
Powered by a proprietary bispecific antibody platform and novel conjugation technology, Allink Biotherapeutics develops next-generation BsADCs characterized by optimized drug-to-antibody ratios (DARs), enhanced hydrophilicity, and superior stability. The company's independent intellectual property portfolio underpins its technological advantages in the field.
Based in Shanghai's Zhangjiang Hi-Tech Park, Allink Biotherapeutics has built a robust pipeline focused on oncology and immunology therapeutics. The company is rapidly advancing multiple lead candidates toward clinical stage in 2024.
Allink was established in 2023
Over 5 patents covering products and technology
Nearly 30 years of experience in biopharmaceutical and ADC R&D
More than 10 innovative pipelines
Experienced R&D Team
Interdisciplinary team with experience in the development of modalities and stage
Efficient Execution
The team successfully delivered 20+ IND applications and secured 3 BLA approvals
Proprietary Platform
Proprietary platform for bispecific antibody and bi-epitope antibody screening
International Collaboration
Fully leverage international collaboration opportunities to accelerate the product development
